vygon (uk) ltd - customer care (01793) 748800
Quality & Innovation in Healthcare
 

Study backs antimicrobials within premistar to prevent infection  

Posted by Vygon UK  on 06-September-2018 
Study backs antimicrobials within premistar to prevent infection

With a study1 proving the innovative antimicrobial technology behind premistar helps protect against infections, there’s no better time for neonatal teams to implement the new peripherally inserted central catheter (PICC).

premistar is the only antimicrobial impregnated 1Fr PICC to provide parenteral nutrition and the administration of medicine for your youngest and most vulnerable patients. 

It encompasses Star Technology combining both Rifampicin and Miconazole to protect against a range of microorganisms including Staphylococci, Enterobacterial and Candida.2

The study led by Dr Nedim Yucel and published in the Journal of Antimicrobial Therapy concluded that CVC supersaturated with Miconazole and Rifampicin were associated with a significantly lower risk for catheter colonisation and catheter-related infections compared to standard catheters.

With more than one million neonatal deaths every year attributed to infection and Neonatal Intensive Care Units (NICU) reporting infection incidence of up to 40% for newborns with a birth weight less than 1000g or <28 gestation, every NICU could benefit from Premistar!

To access the full clinical article click here.

For more information on Premistar visit our aim@zero page http://www.aim-at-zero.co.uk/premistar/ or contact the team today on 01793 748830 or email marketing@vygon.co.uk

For more information please use the Contact Form